Abstract
Purpose of Review
Increased glucose production associated with hepatic insulin resistance contributes to the development of hyperglycemia in T2D. The molecular mechanisms accounting for increased glucose production remain controversial. Our aims were to review recent literature concerning molecular mechanisms regulating glucose production and to discuss these mechanisms in the context of physiological experiments and observations in humans and large animal models.
Recent Findings
Genetic intervention studies in rodents demonstrate that insulin can control hepatic glucose production through both direct effects on the liver, and through indirect effects to inhibit adipose tissue lipolysis and limit gluconeogenic substrate delivery. However, recent experiments in canine models indicate that the direct effects of insulin on the liver are dominant over the indirect effects to regulate glucose production. Recent molecular studies have also identified insulin-independent mechanisms by which hepatocytes sense intrahepatic carbohydrate levels to regulate carbohydrate disposal.
Summary
Dysregulation of hepatic carbohydrate sensing systems may participate in increased glucose production in the development of diabetes.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Cahill GF Jr. Starvation in man. N Engl J Med. 1970;282(12):668–75. https://doi.org/10.1056/NEJM197003192821209.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53.
Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120–6.
Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunengraber H, et al. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes. 1999;48(2):292–8.
Pagliassotti MJ, Cherrington AD. Regulation of net hepatic glucose uptake in vivo. Annu Rev Physiol. 1992;54(1):847–60. https://doi.org/10.1146/annurev.ph.54.030192.004215.
Taylor R, Magnusson I, Rothman DL, Cline GW, Caumo A, Cobelli C, et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest. 1996;97(1):126–32. https://doi.org/10.1172/JCI118379.
Petersen KF, Price T, Cline GW, Rothman DL, Shulman GI. Contribution of net hepatic glycogenolysis to glucose production during the early postprandial period. Am J Phys. 1996;270(1 Pt 1):E186–91. https://doi.org/10.1152/ajpendo.1996.270.1.E186.
Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest. 1996;98(2):378–85. https://doi.org/10.1172/JCI118803.
Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science. 1991;254(5031):573–6.
Nuttall FQ, Ngo A, Gannon MC. Regulation of hepatic glucose production and the role of gluconeogenesis in humans: is the rate of gluconeogenesis constant? Diabetes Metab Res Rev. 2008;24(6):438–58. https://doi.org/10.1002/dmrr.863.
Jahoor F, Peters EJ, Wolfe RR. The relationship between gluconeogenic substrate supply and glucose production in humans. Am J Phys. 1990;258(2 Pt 1):E288–96. https://doi.org/10.1152/ajpendo.1990.258.2.E288.
Baba H, Zhang XJ, Wolfe RR. Glycerol gluconeogenesis in fasting humans. Nutrition. 1995;11(2):149–53.
Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest. 1999;103(3):365–72. https://doi.org/10.1172/JCI5479.
McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 1992;258(5083):766–70.
Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16(2):117–42. https://doi.org/10.1210/edrv-16-2-117.
Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22. https://doi.org/10.1172/JCI77812.
Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97. https://doi.org/10.1016/S1097-2765(05)00015-8.
Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012;15(6):873–84. https://doi.org/10.1016/j.cmet.2012.05.002.
Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–35. https://doi.org/10.1053/j.gastro.2013.11.049.
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–51. https://doi.org/10.1172/JCI23621.
Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003;362(9388):951–7. https://doi.org/10.1016/S0140-6736(03)14364-4.
Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism. 1988;37(1):15–21.
DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387–95.
Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7(2):95–6. https://doi.org/10.1016/j.cmet.2007.12.009.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys. 1979;237(3):E214–23. https://doi.org/10.1152/ajpendo.1979.237.3.E214.
Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism. 1997;46(12 Suppl 1):40–3.
Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163(11):1306–16. https://doi.org/10.1001/archinte.163.11.1306.
White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metab. 2018;27(6):1281–93 e7. https://doi.org/10.1016/j.cmet.2018.04.015.
Chen C, Williams PF, Cooney GJ, Caterson ID, Turtle JR. The effects of fasting and refeeding on liver glycogen synthase and phosphorylase in obese and lean mice. Horm Metab Res. 1992;24(4):161–6. https://doi.org/10.1055/s-2007-1003285.
• Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Coate KC, et al. Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. JCI Insight. 2017;2(6):e91863. https://doi.org/10.1172/jci.insight.91863. This study shows in a canine model that insulin’s acute effects to suppress glucose production is primarily mediated by its direct effects on the liver independently of insulin action on the CNS, adipose tissue, or other peripheral tissue.
Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. https://doi.org/10.1038/nrm1837.
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261–9.
Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 2001;108(9):1359–67. https://doi.org/10.1172/JCI12876.
Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab. 2003;285(4):E718–28. https://doi.org/10.1152/ajpendo.00156.2003.
Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6(3):208–16. https://doi.org/10.1016/j.cmet.2007.08.006.
Haeusler RA, Kaestner KH, Accili D. FoxOs function synergistically to promote glucose production. J Biol Chem. 2010;285(46):35245–8. https://doi.org/10.1074/jbc.C110.175851.
Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A. 2003;100(20):11285–90. https://doi.org/10.1073/pnas.1934283100.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857–68. https://doi.org/10.1016/S0092-8674(00)80595-4.
Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728–31. https://doi.org/10.1126/science.292.5522.1728.
• Titchenell PM, Chu QW, Monks BR, Birnbaum MJ. Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat Commun. 2015;6:7078. https://doi.org/10.1038/ncomms8078 7078. This study shows that when both the insulin receptor and FOXO1 are knocked out of mouse liver, insulin is able to suppress hepatic glucose production by acting on extrahepatic tissues. This indicates that extrahepatic, insulin-mediated mechanisms exist for regulation of glucose production.
Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18(3):388–95. https://doi.org/10.1038/nm.2686.
Okamoto H, Obici S, Accili D, Rossetti L. Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest. 2005;115(5):1314–22. https://doi.org/10.1172/JCI23096.
Boden G, Chen X, Capulong E, Mozzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes. 2001;50(4):810–6.
Sindelar DK, Chu CA, Rohlie M, Neal DW, Swift LL, Cherrington AD. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog. Diabetes. 1997;46(2):187–96.
Rebrin K, Steil GM, Mittelman SD, Bergman RN. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest. 1996;98(3):741–9. https://doi.org/10.1172/JCI118846.
• Perry RJ, Camporez JG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745–58. https://doi.org/10.1016/j.cell.2015.01.012. This study shows that one of insulin’s extrahepatic modes of action to decrease hepatic glucose production is mediated by its inhibitory effect on lipolysis in adipocytes. Additionally, it indicates that high fat diet induced hyperglycemia may result from increased hepatic acetyl-CoA levels produced from oxidation of adipose derived fatty acids.
Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature. 2005;434(7036):1026–31. https://doi.org/10.1038/nature03439.
Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007;5(6):438–49. https://doi.org/10.1016/j.cmet.2007.05.004.
Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002;8(12):1376–82. https://doi.org/10.1038/nm798.
Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006;3(4):267–75. https://doi.org/10.1016/j.cmet.2006.02.009.
Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004;10(2):168–74. https://doi.org/10.1038/nm980.
Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51(12):3391–9. https://doi.org/10.2337/diabetes.51.12.3391.
Ramnanan CJ, Edgerton DS, Cherrington AD. Evidence against a physiologic role for acute changes in CNS insulin action in the rapid regulation of hepatic glucose production. Cell Metab. 2012;15(5):656–64. https://doi.org/10.1016/j.cmet.2012.03.006.
Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116(2):521–7. https://doi.org/10.1172/JCI27073.
Chandramouli V, Ekberg K, Schumann WC, Kalhan SC, Wahren J, Landau BR. Quantifying gluconeogenesis during fasting. Am J Phys. 1997;273(6 Pt 1):E1209–15. https://doi.org/10.1152/ajpendo.1997.273.6.E1209.
Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90(4):1323–7. https://doi.org/10.1172/JCI115997.
Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes. 2000;49(8):1367–73.
Edgerton DS, Ramnanan CJ, Grueter CA, Johnson KM, Lautz M, Neal DW, et al. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes. 2009;58(12):2766–75. https://doi.org/10.2337/db09-0328.
Agius L. Role of glycogen phosphorylase in liver glycogen metabolism. Mol Asp Med. 2015;46:34–45. https://doi.org/10.1016/j.mam.2015.09.002.
Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012;441(3):763–87. https://doi.org/10.1042/BJ20111416.
Wan M, Leavens KF, Hunter RW, Koren S, von Wilamowitz-Moellendorff A, Lu M, et al. A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. Cell Metab. 2013;18(1):99–105. https://doi.org/10.1016/j.cmet.2013.06.001.
Doherty MJ, Cadefau J, Stalmans W, Bollen M, Cohen PT. Loss of the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient glycogen synthesis in insulin-dependent diabetic rats and in adrenalectomized starved rats. Biochem J. 1998;333(Pt 2)(2)):253–7. https://doi.org/10.1042/bj3330253.
Cohen PTW. Protein phosphatase 1 – targeted in many directions. J Cell Sci. 2002;115(2):241–56.
Doherty MJ, Moorhead G, Morrice N, Cohen P, Cohen PT. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. FEBS Lett. 1995;375(3):294–8.
Hansen L, Hansen T, Vestergaard H, Bjorbaek C, Echwald SM, Clausen JO, et al. A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet. 1995;4(8):1313–20. https://doi.org/10.1093/hmg/4.8.1313.
O'Doherty RM, Jensen PB, Anderson P, Jones JG, Berman HK, Kearney D, et al. Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen. J Clin Invest. 2000;105(4):479–88. https://doi.org/10.1172/JCI8673.
Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117(3):739–45. https://doi.org/10.1172/JCI30400.
Raddatz K, Turner N, Frangioudakis G, Liao BM, Pedersen DJ, Cantley J, et al. Time-dependent effects of Prkce deletion on glucose homeostasis and hepatic lipid metabolism on dietary lipid oversupply in mice. Diabetologia. 2011;54(6):1447–56. https://doi.org/10.1007/s00125-011-2073-0.
Brandon AE, Liao BM, Diakanastasis B, Parker BL, Raddatz K, McManus SA, et al. Protein kinase C epsilon deletion in adipose tissue, but not in liver, improves glucose tolerance. Cell Metab. 2019;29(1):183–91 e7. https://doi.org/10.1016/j.cmet.2018.09.013.
Farese RV Jr, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 2012;15(5):570–3. https://doi.org/10.1016/j.cmet.2012.03.004.
Herrera MG, Kamm D, Ruderman N, Cahill. Non-hormonal factors in the control of gluconeogenesis. Adv Enzym Regul. 1966;4:225–35.
Diamond MP, Rollings RC, Steiner KE, Williams PE, Lacy WW, Cherrington AD. Effect of alanine concentration independent of changes in insulin and glucagon on alanine and glucose homeostasis in the conscious dog. Metabolism. 1988;37(1):28–33.
Wolfe RR, Jahoor F, Shaw JH. Effect of alanine infusion on glucose and urea production in man. JPEN J Parenter Enteral Nutr. 1987;11(2):109–11. https://doi.org/10.1177/0148607187011002109.
Steele R, Winkler B, Altszuler N. Inhibition by infused glycerol of gluconeogenesis from other precursors. Am J Phys. 1971;221(3):883–8. https://doi.org/10.1152/ajplegacy.1971.221.3.883.
Shulman GI, Lacy WW, Liljenquist JE, Keller U, Williams PE, Cherrington AD. Effect of glucose, independent of changes in insulin and glucagon secretion, on alanine metabolism in the conscious dog. J Clin Invest. 1980;65(2):496–505. https://doi.org/10.1172/JCI109693.
Jenssen T, Nurjhan N, Consoli A, Gerich JE. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. Demonstration of hepatic autoregulation without a change in plasma glucose concentration. J Clin Invest. 1990;86(2):489–97. https://doi.org/10.1172/JCI114735.
Shulman GI, Liljenquist JE, Williams PE, Lacy WW, Cherrington AD. Glucose disposal during insulinopenia in somatostatin-treated dogs. The roles of glucose and glucagon. J Clin Invest. 1978;62(2):487–91. https://doi.org/10.1172/JCI109150.
Sacca L, Hendler R, Sherwin RS. Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones. J Clin Endocrinol Metab. 1978;47(5):1160–3. https://doi.org/10.1210/jcem-47-5-1160.
Davidson MB. Autoregulation by glucose of hepatic glucose balance: permissive effect of insulin. Metabolism. 1981;30(3):279–84. https://doi.org/10.1016/0026-0495(81)90152-9.
Wahren J, Felig P, Cerasi E, Luft R. Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus. J Clin Invest. 1972;51(7):1870–8. https://doi.org/10.1172/JCI106989.
Toft I, Jenssen T. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production. Scand J Clin Lab Invest. 2005;65(4):307–20. https://doi.org/10.1080/00365510510025692.
• Kim MS, Krawczyk SA, Doridot L, Fowler AJ, Wang JX, Trauger SA, et al. ChREBP regulates fructose-induced glucose production independently of insulin signaling. J Clin Invest. 2016;126(11):4372–86. https://doi.org/10.1172/JCI81993. This study shows that ChREBP-mediated activation of G6PC expression and activity is dominant over insulin’s ability to suppress it. It provides evidence that carbohydrate mediated activation of ChREBP can contribute to hepatic insulin resistance.
Agius L. Dietary carbohydrate and control of hepatic gene expression: mechanistic links from ATP and phosphate ester homeostasis to the carbohydrate-response element-binding protein. Proc Nutr Soc. 2016;75(1):10–8. https://doi.org/10.1017/S0029665115002451.
Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A. 2004;101(19):7281–6. https://doi.org/10.1073/pnas.0401516101.
Agius L. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochem Pharmacol. 2013;85(3):306–12. https://doi.org/10.1016/j.bcp.2012.09.019.
• von Wilamowitz-Moellendorff A, Hunter RW, Garcia-Rocha M, Kang L, Lopez-Soldado I, Lantier L, et al. Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis. Diabetes. 2013;62(12):4070–82. https://doi.org/10.2337/db13-0880. This study provides evidence that G6P mediated activation of glycogen synthase is more important than insulin-mediated regulation of glycogen synthase activity in the regulation of glycogen synthesis.
Aiston S, Andersen B, Agius L. Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase. Diabetes. 2003;52(6):1333–9. https://doi.org/10.2337/diabetes.52.6.1333.
Li MV, Chen W, Harmancey RN, Nuotio-Antar AM, Imamura M, Saha P, et al. Glucose-6-phosphate mediates activation of the carbohydrate responsive binding protein (ChREBP). Biochem Biophys Res Commun. 2010;395(3):395–400. https://doi.org/10.1016/j.bbrc.2010.04.028.
Abdul-Wahed A, Guilmeau S, Postic C. Sweet sixteenth for ChREBP: established roles and future goals. Cell Metab. 2017;26(2):324–41. https://doi.org/10.1016/j.cmet.2017.07.004.
Kim M, Astapova II, Flier SN, Hannou SA, Doridot L, Sargsyan A, et al. Intestinal, but not hepatic, ChREBP is required for fructose tolerance. JCI Insight. 2017;2(24). https://doi.org/10.1172/jci.insight.96703.
Petersen KF, Laurent D, Yu C, Cline GW, Shulman GI. Stimulating effects of low-dose fructose on insulin-stimulated hepatic glycogen synthesis in humans. Diabetes. 2001;50(6):1263–8.
Shiota M, Galassetti P, Monohan M, Neal DW, Cherrington AD. Small amounts of fructose markedly augment net hepatic glucose uptake in the conscious dog. Diabetes. 1998;47(6):867–73.
Shiota M, Moore MC, Galassetti P, Monohan M, Neal DW, Shulman GI, et al. Inclusion of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial hyperglycemia and hyperinsulinemia in the conscious dog. Diabetes. 2002;51(2):469–78.
• Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab. 2015;100(6):2434–42. https://doi.org/10.1210/jc.2014-3678. This study shows that short-term high fructose feeding increases glycogenolysis and glucose production in humans.
Eissing L, Scherer T, Tödter K, Knippschild U, Greve JW, Buurman WA, et al. De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health. Nat Commun. 2013;4:1528. https://doi.org/10.1038/ncomms2537.
Kursawe R, Caprio S, Giannini C, Narayan D, Lin A, D'Adamo E, et al. Decreased transcription of ChREBP-alpha/beta isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes: associations with insulin resistance and hyperglycemia. Diabetes. 2013;62(3):837–44. https://doi.org/10.2337/db12-0889.
Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 2006;55(8):2159–70. https://doi.org/10.2337/db06-0200.
Clore JN, Helm ST, Blackard WG. Loss of hepatic autoregulation after carbohydrate overfeeding in normal man. J Clin Invest. 1995;96(4):1967–72. https://doi.org/10.1172/JCI118243.
Arias AMP, Sauerwein HP, Bisschop PH, Endert E, Ackermans MT, Meijer AJ, et al. The effects of carbohydrate variation in isocaloric diets on glycogenolysis and gluconeogenesis in healthy men*. J Clin Endocrinol Metab. 2000;85(5):1963–7. https://doi.org/10.1210/jcem.85.5.6573.
Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci U S A. 2009;106(29):12121–6. https://doi.org/10.1073/pnas.0812547106.
Haeusler RA, Camastra S, Astiarraga B, Nannipieri M, Anselmino M, Ferrannini E. Decreased expression of hepatic glucokinase in type 2 diabetes. Mol Metab. 2015;4(3):222–6. https://doi.org/10.1016/j.molmet.2014.12.007.
• Bahar Halpern K, Tanami S, Landen S, Chapal M, Szlak L, Hutzler A, et al. Bursty gene expression in the intact mammalian liver. Mol Cell. 2015;58(1):147–56. https://doi.org/10.1016/j.molcel.2015.01.027. This study shows that there is wide variation in the rate of hepatic mRNA turnover and G6PC mRNA turnover is the fastest of all mRNA species robustly detected in the liver. This study underlines the importance of considering metabolic state when harvesting tissues to try to infer molecular mechanisms mediating increased glucose production.
Funding
This work was supported by NIH R01DK100425 (M.A.H.) and American Diabetes Association 1-19-PDF-088 (A.S.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Ashot Sargsyan declares that he has no conflict of interest.
Mark A. Herman reports personal fees from Alkermes Pharmaceuticals and grants from Eli Lilly and Co.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Pathogenesis of Type 2 Diabetes and Insulin Resistance
Rights and permissions
About this article
Cite this article
Sargsyan, A., Herman, M.A. Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes. Curr Diab Rep 19, 77 (2019). https://doi.org/10.1007/s11892-019-1195-5
Published:
DOI: https://doi.org/10.1007/s11892-019-1195-5